Syndax Pharmaceuticals, Inc. (SNDX)
FDA Delays Decision on Syndax Leukemia Drug; Stock Sinks
Shares of Syndax Pharmaceuticals (SNDX) plunged in intraday trading Monday after the biopharmaceutical company reported that the Food and Drug Administration (FDA) delayed a decision on approving its experimental treatment for acute leukemia.
Wall Street Analysts Think Syndax (SNDX) Could Surge 50.26%: Read This Before Placing a Bet
The consensus price target hints at a 50.3% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Syndax (SNDX) Could Rally 67.11%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 67.1% in Syndax (SNDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
